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ABSTRACT
ObjectiveaaGender differences are a well-known clinical characteristic of Parkinson’s disease (PD). In-vivo imaging studies dem-
onstrated that women have greater striatal dopamine transporter (DAT) activity than do men, both in the normal population and 
in PD patients. We hypothesize that women exhibit more rapid aging-related striatal DAT reduction than do men, as the potential 
neuroprotective effect of estrogen wanes with age.
MethodsaaThis study included 307 de novo PD patients (152 men and 155 women) who underwent DAT scans for an initial diag-
nostic work-up. Gender differences in age-related DAT decline were assessed in striatal sub-regions using linear regression analysis. 
ResultsaaFemale patients exhibited greater DAT activity compared with male patients in all striatal sub-regions. The linear re-
gression analysis revealed that age-related DAT decline was greater in the anterior and posterior caudate, and the anterior puta-
men in women compared with men; we did not observe this difference in other sub-regions.
ConclusionsaaThis study demonstrated the presence of gender differences in age-related DAT decline in striatal sub-regions, par-
ticularly in the antero-dorsal striatum, in patients with PD, presumably due to aging-related decrease in estrogen. Because this dif-
ference was not observed in the sensorimotor striatum, this finding also suggests that women may not have a greater capacity to 
tolerate PD pathogenesis than do men.
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Gender differences are a well-known clinical characteristic 
of Parkinson’s disease (PD).1 PD occurs more often in men than 
in women: a meta-analysis showed an increased relative risk of 
1.5 in men.2 Age at PD onset is later in women than in men,3,4 
and partly correlates with fertile life span in women.3 Clinically, 
women with PD exhibit less severe PD motor features, and show 
greater levodopa responses with more severe levodopa-induced 
dyskinesia.5,6 Female sex hormones (i.e., estrogen) are thought 
to play an important role in the gender differences observed in 
PD.7 These gender differences suggest a beneficial influence of 
estrogens against the development and progression of PD. 
Women also show higher striatal dopamine transporter (DAT) 
activity than do men, both in the normal population and in pa-
tients with PD.3,8-11 This gender-related DAT difference is more 
prominent in the caudate than in the putamen.8 In addition, 
striatal DAT activity declines with aging, both in the normal po-
pulation8-13 and in patients with PD.8,11 The age-related decline 
in DAT activity mainly impacts the striatum in controls,8,11,14 and 
the caudate in patients with PD.12 If greater DAT activity in wo-
men is related to the potential neuroprotective effects of estro-
gen, age-related DAT decline may be greater in women than in 
men, as the effects of estrogen wane with aging. Therefore, in 
this study, we investigated gender differences in the degree and 
pattern of aging-related striatal DAT decline in patients with PD.
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MATERIALS & METHODS
Patients 
Study subjects were selected from the Yonsei Par-
kinson Center database (patient sample collected 
from March 2009 to June 2013) and fulfilled the fol-
lowing selection criteria: 1) drug-naive PD patients, 
2) who underwent DAT imaging, using [18F] N-(3-
fluoropropyl)-2β-carbon ethoxy-3β-(4-iodophenyl) 
nortropane positron emission tomography (FP-CIT-
PET) scans, and 3) who had intact cognitive function 
(Mini-Mental Status Examination score of 24 or high-
er). In these patients, PD was diagnosed according 
to the clinical criteria of the United Kingdom PD so-
ciety Brain Bank,15 the presence of appropriate DAT 
uptake defects on FP-CIT PET scans,16 and the pres-
ence of anti-Parkinson drug response during fol-
low-up (i.e., after 6 or more months of PD medication 
administration). Part III of the Unified Parkinson 
Disease Rating Scale (UPDRS-motor) was used to 
assess PD severity in each patient at the time of 18F-
FP-CIT PET image acquisition. The ethics commit-
tee of our hospital reviewed and approved this study.
PET-CT image acquisition
To assess striatal dopamine depletion, we obtained 
DAT scans using 18F-FP-CIT with a GE Discovery 
STe (DSTE) PET-CT scanner (GE Healthcare Tech-
nologies, Milwaukee, WI, USA). Each patient fasted 
for 6 hours before receiving an intravenous injec-
tion of 5 mCi (185 MBq) 18F-FP-CIT. Ninety min-
utes after the injection, DAT images were obtained 
in 3 dimensional (3D) mode during a 20-minute ses-
sion. Post hoc 3D Gaussian smoothing with a 2.3-
mm full-width half-maximum was performed. For 
localization and attenuation correction, CT images 
were acquired at 120 KVp and 380 mAs after PET 
scanning.
Quantitative analysis of the PET image data
Quantitative analyses of FP-CIT PET data were 
performed according to a previously published pro-
cedure.16 Images were processed using SPM8 (Well-
come Department of Imaging Neuroscience, Insti-
tute of Neurology, University College London, Lon-
don, UK) with MATLAB 2013a for Windows (Math-
Works, Natick, MA, USA). Quantitative analyses 
were based on volumes of interest (VOIs), which were 
defined based on a template in standard space. All 
reconstructed PET images were spatially normal-
ized to the Montreal Neurological Institute template 
space using a standard FP-CIT PET template, as 
described previously.16 Twelve VOIs of both striatal 
sub-regions and one occipital VOI were drawn on a 
co-registered spatially normalized single T1 MRI and 
a FP-CIT PET template image using MRIcro ver-
sion 1.37 (Chris Rorden, Columbia, SC, USA). DAT 
activity in each VOI was estimated as the surrogate 
of non-displaceable binding potential, defined as 
follows: [mean standardized uptake value (SUV) of 
the striatal sub-regions VOI - mean SUV of the oc-
cipital VOI] / mean SUV of the occipital VOI.17 Mean 
DAT activities of bilateral striatal sub-regions were 
used in the statistical analyses.
Statistical analysis 
Data are expressed as means ± SDs. Unpaired t-
tests were used to compare clinical and DAT data be-
tween genders. An analysis of covariance with adjust-
ment for age of onset was conducted to identify 
disparities in DAT activity and inter-sub-regional ra-
tios (ISRs) between genders. General linear model 
and linear regression analyses controlled for age of 
onset, gender, disease duration, and UPDRS-motor 
scores, were performed to determine differences in 
age-related decline of DAT activity between gen-
ders. SPSS Statistics 20 (IBM, Armonk, NY, USA) 
was used to perform all statistical analyses. p-values 
< 0.05 were regarded as statistically significant.
RESULTS
A total of 307 patients (152 men and 155 women) 
were included in the data analysis. The mean age of 
onset was 63.8 ± 9.8 (range, 37.0–85.4), the mean 
symptom duration was 1.4 ± 1.1 years, and the mean 
UPDRS-motor score was 22.4 ± 10.4. Baseline clini-
cal characteristics are summarized in Table 1. All 
clinical variables were comparable between genders. 
Striatal sub-regional DAT activities and ISRs are 
shown in Table 2. Female patients exhibited greater 
DAT activities in all striatal sub-regions than did 
male patients. Female patients also had higher ISRs 
in the anterior caudate/posterior putamen and in 
the posterior caudate/posterior putamen: the ISRs 
were comparable in other striatal sub-regions. 
Female patients exhibited greater age-related de-
cline in DAT activity in all striatal sub-regions except 
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for the posterior putamen (Figure 1). After control-
ling for the influence of age of onset, the age-related 
decline in DAT activity was still significantly steeper 
in the anterior putamen and in the anterior and the 
posterior caudate. The DAT activity tended to be 
steeper in the ventral striatum in female versus male 
patients, but was comparable in the ventral and the 
posterior putamen between genders (Table 3). The 
same analysis was performed after controlling the 
influence of age of PET scan, instead of age of onset, 
and yielded similar results (Supplementary Table 1 
in the online-only Data Supplement).
DISCUSSION 
This study demonstrated that female patients sh-
owed greater DAT activity in all striatal sub-regions 
than did male patients. However, in this study, fe-
male patients also exhibited a more rapid age-related 
decline in DAT activity than did male patients, par-
ticularly in striatal sub-regions other than the sen-
sorimotor striatum. We used age of onset in the sta-
tistical analyses performed in this study, because we 
primarily focused the influence of gender on striatal 
DAT activity at the time of PD onset (i.e., we assum-
ed that the protective effect of female sex hormone 
could affect PD onset). In the analyses controlling 
for age of PET scans instead of age of onset showed 
similar results. Clinical variables were comparable 
between genders in this study, a finding that is in 
contrast to previous studies that reported later PD 
onset and less motor deficits in women than men 
with PD.3-6 In this study, male patients exhibited lat-
er PD onset of 1.7 years than female patients, but this 
difference did not attain statistical significance.
Our finding of greater striatal DAT activity in wo-
men compared with men is consistent with a num-
ber of previous studies. In healthy individuals, wo-
men have significantly greater striatal DAT activity 
than do men.9,18,19 A previous study that evaluated 
postsynaptic dopamine receptor activity using 11C-
raclopride PET also reported a similar finding in 
healthy individuals.20 In PD, two studies using 123I- 
FP-CIT single photon emission computed tomog-
raphy (SPECT) revealed higher striatal DAT binding 
in female than male patients.3,8 Haaxma et al.3 re-
ported that women had 16% higher striatal FP-CIT 
binding than men at symptom onset, while Kaasinen 
et al.8 showed that women had greater DAT binding 
in the caudate, but not in the putamen. Because of 
the limited spatial resolution of the SPECT scan, 
they could not measure DAT activity in each striatal 
sub-region. We were able to subdivide striatal DAT 
activity into six sub-regions due to the superior spa-
tial resolution of PET scanning, and found that gr-
eater DAT activity was present in all striatal sub-re-
gions in women compared with men. Furthermore, 
we then analyzed ISRs, and found that women had 
higher ISRs in the anterior caudate/posterior puta-
men and in the posterior caudate/posterior puta-
men. Higher ISRs in women in this study may rep-
resent either greater DAT activities in the anterior 
and posterior caudate relative to those in the poste-
rior putamen or less DAT activities in the posterior 
putamen relative to those in the anterior and poste-
Table 1. Baseline clinical characteristics 
Variables Men (n = 152) Women (n = 155) p
Age at diagnosis, yr 66.1 ± 9.7 64.4 ± 9.7 n.s.
Age of onset, yr 64.6 ± 9.6 62.9 ± 9.9 n.s.
Symptom duration, yr 1.4 ± 1.1 1.4 ± 1.2 n.s.
UPDRS-motor score 22.0 ± 10.2 22.9 ± 10.6 n.s.
MMSE score 27.4 ± 1.9 27.1 ± 1.8 n.s.
Data are expressed as means ± SDs. UPDRS: Unified Parkinson’s Disease Rating Scale, 
MMSE: Mini-Mental State Examination, n.s.: not significant, SD: standard deviation.
Table 2. Striatal sub-regional dopamine transporter activities and inter-sub-regional 
ratios
Men 
(n = 152)
Women 
(n = 155)
p*
Striatal sub-regions
Anterior caudate 1.88 ± 0.64 2.33 ± 0.76 < 0.001
Posterior caudate 1.14 ± 0.43 1.46 ± 0.54 < 0.001
Ventral striatum 2.22 ± 2.58 2.49 ± 0.61 < 0.001
Anterior putamen 1.97 ± 0.60 2.28 ± 0.67 < 0.001
Posterior putamen 1.15 ± 0.43 1.34 ± 0.54 0.001
Ventral putamen 1.29 ± 0.38 1.53 ± 0.48 < 0.001
Inter-sub-regional ratios
Anterior caudate/posterior putamen 1.72 ± 0.57 1.86 ± 0.56 0.031
Anterior putamen/posterior putamen 1.77 ± 0.42 1.79 ± 0.38 0.766
Posterior caudate/posterior putamen 1.04 ± 0.36 1.15 ± 0.37 0.006
Ventral striatum/posterior putamen 2.08 ± 0.73 2.01 ± 0.54 0.386
Data are expressed as means ± SDs. *adjusted for age of onset. SD: standard deviation.
Table 3. Estimated slopes of age-related DAT decline in the striatal sub-regions
Striatal sub-regions Men (n = 152) Women (n = 155) p*
Anterior caudate -0.018 (0.006) -0.043 (0.007) 0.004
Posterior caudate -0.011 (0.004) -0.030 (0.005) 0.003
Ventral striatum -0.008 (0.005) -0.022 (0.006) 0.073
Anterior putamen -0.003 (0.005) -0.022 (0.006) 0.013
Posterior putamen 0.002 (0.004) -0.015 (0.040) 0.424
Ventral putamen -0.004 (0.003) -0.012 (0.004) 0.121
Data are estimated slopes (SEs). *adjusted for age of onset, symptom duration, and UP-
DRS-motor scores. UPDRS: Unified Parkinson’s Disease Rating Scale, DAT: dopamine 
transporter, SE: standard error.
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Figure 1. Scatterplots showing the age of onset and dopamine transporter (DAT) activity in the striatal sub-regions. A: Anterior caudate. B: 
Posterior caudate. C: Ventral striatum. D: Anterior putamen. E: Posterior putamen. F: Ventral putamen. In all sub-regions, women (closed 
triangle) exhibited higher DAT activities than did men (open circle). Women (dotted line) showed a more rapid age-related DAT decline in 
the anterior caudate (A), posterior caudate (B), and the anterior putamen (D), compared with men (solid line). 
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rior caudate. Because women exhibited greater DAT 
activities in all striatal sub-regions than did men, 
we could disregard the latter possibility. Thus, these 
findings suggest that the gender-related DAT activ-
ity difference is greater in the caudate compared with 
the putamen, which is partly compatible with the fi-
ndings of Kaasinen et al.8 
The age-related striatal DAT decline observed in 
this study was also demonstrated in a number of 
previous studies.9-13 However, the effect of gender on 
striatal DAT activity has been controversial. Lavalaye 
et al.9 observed that the effect of gender on 123I-FP-
CIT binding ratios was not related to age, while 
Wong et al.10 demonstrated that DAT activity signif-
icantly differed between genders in their young-to-
middle age group (< 60 years), but not in the elderly 
age group. The present study supports Wong et al.’s 
findings, and illustrates that gender differences in 
age-related striatal DAT decline is also present in pa-
tients with PD. Furthermore, this study also demon-
strated that gender differences in age-related DAT 
decline was more prominent in the other striatal 
sub-regions than in the ventral and posterior puta-
men. The striatum is organized into sensorimotor, 
associative, and limbic regions: the motor and pre-
motor cortex project to the posterior and ventral pu-
tamen, and control sensorimotor function (i.e., the 
sensorimotor stratum).21,22 Because PD pathology 
preferentially affects the sensorimotor striatum, pro-
ducing the motor deficits of PD, our findings sug-
gest that PD-related pathology in the sensorimotor 
striatum contributes to the loss of gender effects on 
age-related DAT decline. Lee et al.11 reported that 
age-related decline in DAT binding was preserved 
in the caudate, but was lost in the putamen of pa-
tients with PD. The authors suggested that differen-
tial age effects in the parkinsonian striatum likely 
reflect the superimposition of disease-driven com-
pensation on the aging effect. Thus, our results may 
represent the superimposition of PD-driven influ-
ence on the gender effect.
Our study demonstrated that women had greater 
striatal DAT activity than did men, and women ex-
hibited a more rapid decline of this activity with ag-
ing: the reason for this is unclear. A previous review 
suggested that the beneficial effects of estrogen con-
tributed to this phenomenon.7 Animal experiments 
showed that estrogen protects dopaminergic neu-
rons against various neurotoxins that induce PD-like 
symptoms, by promoting survival factors, activating 
signaling pathways, interacting with growth factors, 
and exerting an anti-aggregation effect on alpha-sy-
nuclein.7,23-25 Clinically, hormone replacement ther-
apy with estrogen lowers the risk of PD and amelio-
rates motor deficits in PD.26-28 The development and 
severity of PD are associated with lower lifetime es-
trogen exposure or shorter fertile life span.29,30 These 
observations suggest that fertile life with sufficient 
estrogen maintenance in women has a key role in 
protecting striatal dopaminergic neurons against 
aging-related processes, and in maintaining a greater 
number of dopaminergic neurons during fertile life 
compared with men. This protective effect of estro-
gen may wane with aging (i.e., at the end of fertile 
life), which results in a more rapid age-related de-
cline in dopaminergic neurons in women than in 
men, as observed in this study. Thus, the lack of a 
gender effect in age-related DAT decline in the sen-
sorimotor striatum in this study suggests that the ef-
fect of estrogen in women can protect dopaminergic 
neurons against age-related processes, but not ag-
ainst PD-related pathogenesis.
In this study, measurements of striatal DAT activ-
ity and UPDRS-motor scores were conducted in 
drug-naive patients, sufficiently excluding the influ-
ence of any PD medication on the present results. 
A programmed measure of striatal DAT activities 
could minimize the inter-rater and intra-rater vari-
ability. However, this study had few notable limita-
tions. Primarily, this study could not completely ex-
clude the possibility of atypical parkinsonian syn-
dromes due to the enrollment of early-stage patients 
with PD and a relatively short follow-up. Secondly, 
the lack of data from healthy controls precluded a 
comparison of the present results with normal age-
related changes in striatal DAT activity. Thus, a fur-
ther study that includes a sufficient number of he-
althy controls is warranted to address whether the 
findings observed in the present study are PD-spe-
cific or not.
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Posterior putamen 0.002 (0.004) -0.003 (0.004) 0.342
Ventral putamen -0.004 (0.003) -0.012 (0.004) 0.097
Data are estimated slopes (SEs). *adjusted for age of PET scans, symptom duration, and UPDRS-motor scores. UPDRS: Unified 
Parkinson’s Disease Rating Scale, DAT: dopamine transporter, PET: positron emission tomography, SE: standard error.
